- Increases First Quarter Revenues 12%
to $4.9 Billion
- Posts First Quarter GAAP EPS of
$0.94 and Non-GAAP EPS of $0.84
- Achieves Key Regulatory Milestones
For Opdivo in the U.S. and Europe
- Advances Immuno-Oncology
Collaborations with Incyte and Exelixis to include Phase 3
Trials
- Increases 2017 GAAP and Non-GAAP EPS
Guidance
Bristol-Myers Squibb Company (NYSE:BMY) today reported results
for the first quarter of 2017, which were highlighted by strong
sales for key products Opdivo and Eliquis, regulatory approval for
Opdivo in advanced bladder cancer in the U.S., positive opinions
from the Committee for Medicinal Products for Human Use (CHMP) for
advanced bladder and head and neck cancers in Europe, and strategic
transactions in oncology that further strengthened the company’s
pipeline.
“During the first quarter we delivered strong sales and earnings
growth, achieved important regulatory milestones for Opdivo in the
U.S. and Europe and presented important new data across our
Immuno-Oncology and fibrosis portfolios,” said Giovanni Caforio,
M.D., chief executive officer, Bristol-Myers Squibb. “Building on
this strong start to the year, we will continue to drive commercial
performance in the short-term while advancing important
opportunities to broaden our approach in Immuno-Oncology and
progressing our early specialty portfolio.”
First
Quarter
$ amounts in millions, except per share amounts
2017
2016
Change
Total Revenues $4,929 $4,391 12% GAAP Diluted EPS 0.94 0.71 32%
Non-GAAP Diluted EPS 0.84 0.74 14%
FIRST QUARTER FINANCIAL
RESULTS
- Bristol-Myers Squibb posted first
quarter 2017 revenues of $4.9 billion, an increase of 12% compared
to the same period a year ago. Revenues increased 13% when adjusted
for foreign exchange impact.
- U.S. revenues increased 8% to $2.7
billion in the quarter compared to the same period a year ago.
International revenues increased 18%. When adjusted for foreign
exchange impact, international revenues increased 20%.
- Gross margin as a percentage of revenue
decreased from 76.0% to 74.5% in the quarter primarily due to
product mix.
- Marketing, selling and administrative
expenses increased 1% to $1.1 billion in the quarter.
- Research and development expenses
increased 13% to $1.3 billion in the quarter.
- The effective tax rate was 21.9% in the
quarter, compared to 27.1% in the first quarter last year.
- The company reported net earnings
attributable to Bristol-Myers Squibb of $1.6 billion, or $0.94 per
share, in the first quarter compared to net earnings of $1.2
billion, or $0.71 per share, for the same period in 2016. The
results for the first quarter of 2017 included Bristol-Myers
Squibb’s share of a patent-infringement litigation settlement
related to Merck’s PD-1 antibody Keytruda® that contributed $0.18
per share.
- The company reported non-GAAP net
earnings attributable to Bristol-Myers Squibb of $1.4 billion, or
$0.84 per share, in the first quarter, compared to $1.2 billion, or
$0.74 per share, for the same period in 2016. An overview of
specified items is discussed under the “Use of Non-GAAP Financial
Information” section.
- Cash, cash equivalents and marketable
securities were $8.8 billion, with a net cash position of $360
million, as of March 31, 2017.
FIRST QUARTER PRODUCT AND PIPELINE
UPDATE
Product Sales/Business Highlights
The increase in global revenues for the first quarter of 2017,
compared to the first quarter of 2016, was driven by:
Product
Growth
%
Opdivo 60% Eliquis 50%
Yervoy
25%
Sprycel
14%
Orencia
13%
Opdivo
Regulatory
- In April, the company announced the
CHMP recommended the approval of Opdivo for the treatment of
patients with locally advanced unresectable or metastatic
urothelial carcinoma (mUC) in adults after failure of prior
platinum-containing chemotherapy. The CHMP recommendation will be
reviewed by the European Commission (EC), which has the authority
to approve medicines for the European Union (EU).
- In April, the company announced the
U.S. Food and Drug Administration (FDA) accepted a supplemental
Biologics License Application seeking to extend the use of Opdivo
to patients with mismatch repair deficient or microsatellite
instability high metastatic colorectal cancer after prior
fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
The FDA granted the application priority review and the FDA action
date is August 2, 2017.
- In April, the FDA approved an updated
indication for Opdivo for the treatment of adult patients with
Classical Hodgkin lymphoma that have relapsed or progressed after
autologous hematopoietic stem cell transplantation (HSCT) and
brentuximab vedotin, or three or more lines of systemic therapy
that includes autologous HSCT. This indication is approved under
accelerated approval based on overall response rate. Continued
approval for this indication may be contingent upon verification
and description of clinical benefit in confirmatory trials.
- In March, the company announced the
CHMP recommended the approval of Opdivo as monotherapy for the
treatment of squamous cell cancer of the head and neck in adults
progressing on or after platinum-based therapy. The CHMP
recommendation will be reviewed by the EC.
- In March, the company and its partner
Ono Pharmaceutical Co. announced the approval of Opdivo as
monotherapy for the treatment of recurrent or metastatic head and
neck cancer in Japan.
- In February, the company announced the
FDA provided accelerated approval for Opdivo for the treatment of
patients with locally advanced or metastatic urothelial carcinoma
who have disease progression during or following
platinum-containing chemotherapy or have disease progression within
12 months of neoadjuvant or adjuvant treatment with
platinum-containing chemotherapy.
Clinical
- In April, at the American Association
for Cancer Research (AACR) Annual Meeting, the company announced
new data and analysis from studies evaluating Opdivo and the Opdivo
+ Yervoy regimen:
- First overall survival results from
CheckMate -067, a Phase 3 trial of Opdivo and the Opdivo + Yervoy
regimen versus Yervoy alone in patients with previously untreated
advanced melanoma. More detail of the study results is included in
the original press release (link).
- The first report of five-year overall
survival data from the Phase 1 dose-ranging study CA209-003
evaluating Opdivo in patients with previously treated advanced
non-small cell lung cancer. More detail of the study results is
included in the original press release (link).
- In April, the company announced
CheckMate -143, a randomized Phase 3 clinical trial evaluating the
efficacy and safety of Opdivo in patients with first recurrence of
glioblastoma multiforme did not meet its primary endpoint of
improved overall survival over bevacizumab monotherapy.
Sprycel
- In February, the company announced the
European Patent Office (EPO) upheld a decision finding European
Patent No. 1169038 (the '038 patent), the Composition of Matter
patent covering dasatinib, the active ingredient in Sprycel, to be
invalid. The decision does not impact patents outside of the EU or
other Sprycel-related patents. Additionally in February, the EPO
Board of Appeal reversed and remanded an invalidity decision on
European Patent No. 1610780 and its claim to the use of dasatinib
to treat chronic myeloid leukemia (CML), which the EPO's Opposition
Division had revoked in October 2012. The company intends to take
appropriate legal actions to protect Sprycel.
Eliquis
- In March, at the American College of
Cardiology’s (ACC) Annual Scientific Session, the company and its
partner Pfizer Inc. announced findings from a real-world data
analysis of the U.S. Medicare database comparing the risk of stroke
or systemic embolism and rate of major bleeding among patients with
non-valvular atrial fibrillation who were treated with direct oral
anticoagulants Eliquis, dabigatran or rivaroxaban versus warfarin.
More detail of the analysis is included in the original press
release (link).
Fibrosis
- In April, at EASL: The International
Liver Congress, the company announced data from a Phase 2 study of
BMS-986036, an investigational pegylated analogue of human
fibroblast growth factor 21 (FGF21), a key regulator of metabolism,
in patients with biopsy-confirmed non-alcoholic steatohepatitis
(NASH ) (F1-F3). The study achieved its primary endpoint of
significant reduction in liver fat versus placebo, and also showed
improvement in markers of liver injury and fibrosis.
FIRST QUARTER BUSINESS DEVELOPMENT
UPDATE
- In April, the company and Transgene
announced a clinical research collaboration to evaluate the safety,
tolerability and efficacy of Transgene’s investigational
therapeutic vaccine TG4010 in combination with Opdivo + standard
chemotherapy (CT) as a first-line treatment for advanced
non-squamous non-small cell lung cancer (NSCLC) in patients whose
tumors have low or undetectable levels of PD-L1.
- In April, the company and Apexigen,
Inc. announced a clinical trial collaboration to evaluate the
safety, tolerability and preliminary efficacy of Apexigen’s APX005M
with Opdivo in patients with second-line metastatic NSCLC who have
failed prior chemotherapy, and in metastatic melanoma patients who
have failed prior Immuno-Oncology (I-O) therapy.
- In April, the company and Nordic
Bioscience announced a collaboration to develop biomarker
technology to potentially aid in the diagnosis and monitoring of
fibrotic diseases including NASH.
- In April, the company announced it
entered into two separate agreements to outlicense BMS-986168, an
anti-eTau compound in development for Progressive Supranuclear
Palsy, to Biogen, and BMS-986089, an anti-myostatin adnectin in
development for Duchenne Muscular Dystrophy, to Roche. The company
will receive upfront payments of $300 million from Biogen and $170
million from Roche, along with potential milestone payments and
royalties from each company.
- In April, the company and Incyte
Corporation announced an agreement to advance their clinical
development program evaluating the combination of epacadostat,
Incyte’s investigational oral selective IDO1 enzyme inhibitor, with
Opdivo into Phase 3 registrational studies in first-line NSCLC
across the spectrum of PD-L1 expression and first-line head and
neck cancer. Additionally, the companies are expanding the ECHO-204
Phase 1/2 study, established under a collaboration between the
companies in 2014, to include anti-PD-1/PD-L1 relapsed/refractory
melanoma cohorts.
- In March, the company and Foundation
Medicine announced a collaboration to leverage Foundation
Medicine’s comprehensive genomic profiling and molecular
information solutions to identify predictive biomarkers such as
Tumor Mutational Burden and Microsatellite Instability in patients
enrolled across clinical trials investigating Bristol-Myers
Squibb’s cancer immunotherapies.
- In March, the company, the Parker
Institute for Cancer Immunotherapy and the Cancer Research
Institute (CRI) announced a multi-year collaboration agreement to
coordinate and rapidly initiate clinical I-O studies across the
Parker Institute and CRI networks.
- In March, the company and CytomX
Therapeutics, Inc. announced an expansion of their collaboration to
discover novel therapies against multiple I-O targets using
CytomX’s proprietary Probody® Platform, expanding the number of
targets from four to twelve.
- In March, the company announced an
equity investment and plans for a research collaboration with GRAIL
Inc. that grants the company early access to GRAIL’s comprehensive
clinical trial databases that may help improve understanding of
tumor genomics. Additionally, Bristol-Myers Squibb will utilize
GRAIL’s analytics tools to inform research, advance diagnostics and
improve patient outcomes.
- In February, the company and Exelixis,
Inc. announced a clinical development collaboration to evaluate
Cabometyx® (cabozantinib), Exelixis’ small molecule inhibitor of
receptor tyrosine kinases, with Opdivo, either alone or in
combination with Yervoy. The agreement is expected to include a
Phase 3 pivotal trial in first-line renal cell carcinoma, with
additional trials planned in bladder cancer, hepatocellular
carcinoma (HCC), and potentially other tumor types.
- In February, the company announced an
expansion of the five-year old International Immuno-Oncology
Network (II-ON) with the addition of Columbia University Medical
Center and Peter MacCallum Cancer Centre (Peter Mac). II-ON is a
global peer-to-peer collaboration between Bristol-Myers Squibb and
academia that aims to advance I-O science and translational
medicine to improve patient outcomes.
SHARE REPURCHASE
In February, the company executed accelerated share repurchase
(ASR) agreements to repurchase, in aggregate, $2 billion of the
company’s common stock. The ASR was funded through a combination of
debt and cash and is part of the company’s existing share
repurchase authorization. Approximately 80 percent of the shares to
be repurchased under the transaction were received by the company
on February 28, 2017 and the company anticipates that all
repurchases under the ASR will be completed by the end of the
second quarter of 2017.
The decision reflects the company’s strong financial position
and its balanced approach to capital allocation, including a
commitment to its dividend and a disciplined approach to business
development.
2017 FINANCIAL GUIDANCE
Bristol-Myers Squibb is increasing its 2017 GAAP EPS guidance
range from $2.47- $2.67 to $2.72 - $2.87 and is increasing its
non-GAAP EPS guidance range from $2.70 - $2.90 to $2.85 - $3.00.
Both GAAP and non-GAAP guidance assume current exchange rates. Key
revised 2017 GAAP and non-GAAP line-item guidance assumptions
are:
- Worldwide revenues increasing in the
mid-single digits.
- Research and development expenses
increasing in the high-teens digit range for GAAP and increasing in
the low-double digits range for non-GAAP.
- An effective tax rate of approximately
22% for GAAP with non-GAAP remaining at approximately 21%.
The financial guidance excludes the impact of any potential
future strategic acquisitions and divestitures and any specified
items that have not yet been identified and quantified. The
non-GAAP guidance also excludes other specified items as discussed
under “Use of Non-GAAP Financial Information.” Details reconciling
GAAP amounts to non-GAAP amounts, with non-GAAP reflecting
specified items are provided in supplemental materials attached to
this press release and available on the company’s website.
Keytruda® is a trademark of Merck & Co., Inc.Probody®
Platform is a trademark of CytomX Therapeutics, Inc.Cabometyx® is a
trademark of Exelixis, Inc.
Use of Non-GAAP Financial
Information
This press release contains non-GAAP financial measures,
including non-GAAP earnings and related EPS information, that are
adjusted to exclude certain costs, expenses, gains and losses and
other specified items that are evaluated on an individual basis.
These items are adjusted after considering their quantitative and
qualitative aspects and typically have one or more of the following
characteristics, such as being highly variable, difficult to
project, unusual in nature, significant to the results of a
particular period or not indicative of future operating results.
Similar charges or gains were recognized in prior periods and will
likely reoccur in future periods including restructuring costs,
accelerated depreciation and impairment of property, plant and
equipment and intangible assets, R&D charges in connection with
the acquisition or licensing of third party intellectual property
rights, divestiture gains or losses, upfront payments from out
licensed assets, pension charges, legal and other contractual
settlements and debt redemption gains or losses, among other items.
Deferred and current income taxes attributed to these items are
also adjusted for considering their individual impact to the
overall tax expense, deductibility and jurisdictional tax rates.
Non-GAAP information is intended to portray the results of our
baseline performance, supplement or enhance management, analysts
and investors overall understanding of our underlying financial
performance and facilitate comparisons among current, past and
future periods. For example, non-GAAP earnings and EPS information
is an indication of our baseline performance before items that are
considered by us to not be reflective of our ongoing results. In
addition, this information is among the primary indicators we use
as a basis for evaluating performance, allocating resources,
setting incentive compensation targets and planning and forecasting
for future periods. This information is not intended to be
considered in isolation or as a substitute for net earnings or
diluted EPS prepared in accordance with GAAP.
Statement on Cautionary
Factors
This press release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 regarding, among other things, statements relating to
goals, plans and projections regarding the company’s financial
position, results of operations, market position, product
development and business strategy. These statements may be
identified by the fact that they use words such as "anticipate",
"estimates", "should", "expect", "guidance", "project", "intend",
"plan", "believe" and other words and terms of similar meaning in
connection with any discussion of future operating or financial
performance. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them,
and could cause actual outcomes and results to differ materially
from current expectations. These factors include, among other
things, effects of the continuing implementation of governmental
laws and regulations related to Medicare, Medicaid, Medicaid
managed care organizations and entities under the Public Health
Service 340B program, pharmaceutical rebates and reimbursement,
market factors, competitive product development and approvals,
pricing controls and pressures (including changes in rules and
practices of managed care groups and institutional and governmental
purchasers), economic conditions such as interest rate and currency
exchange rate fluctuations, judicial decisions, claims and concerns
that may arise regarding the safety and efficacy of in-line
products and product candidates, changes to wholesaler inventory
levels, variability in data provided by third parties, changes in,
and interpretation of, governmental regulations and legislation
affecting domestic or foreign operations, including tax
obligations, changes to business or tax planning strategies,
difficulties and delays in product development, manufacturing or
sales including any potential future recalls, patent positions and
the ultimate outcome of any litigation matter. These factors also
include the company’s ability to execute successfully its strategic
plans, including its business development strategy, the expiration
of patents or data protection on certain products, including
assumptions about the company’s ability to retain patent
exclusivity of certain products, and the impact and result of
governmental investigations. There can be no guarantees with
respect to pipeline products that future clinical studies will
support the data described in this release, that the compounds will
receive necessary regulatory approvals, or that they will prove to
be commercially successful; nor are there guarantees that
regulatory approvals will be sought, or sought within currently
expected timeframes, or that contractual milestones will be
achieved. For further details and a discussion of these and other
risks and uncertainties, see the company's periodic reports,
including the annual report on Form 10-K, quarterly reports on Form
10-Q and current reports on Form 8-K, filed with or furnished to
the Securities and Exchange Commission. The company undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Company and Conference Call Information
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
There will be a conference call on April 27, 2017 at 10:30 a.m.
EDT during which company executives will review financial
information and address inquiries from investors and analysts.
Investors and the general public are invited to listen to a live
webcast of the call at http://investor.bms.com or by calling the
U.S. toll free 855-303-0072 or international 913-312-0976,
confirmation code: 500711. Materials related to the call will be
available at the same website prior to the conference call. A
replay of the call will be available beginning at 1:30 p.m. EDT on
April 27, 2017 through 1:30 p.m. EDT on May 11, 2017. The replay
will also be available through http://investor.bms.com or by
calling the U.S. toll free 888-203-1112 or international
719-457-0820, confirmation code: 6160500.
BRISTOL-MYERS SQUIBB COMPANY
PRODUCT REVENUE
FOR THE THREE MONTHS ENDED MARCH 31,
2017 AND 2016
(Unaudited, dollars in millions)
Worldwide Revenues U.S. Revenues 2017 2016 %
Change
2017 2016 %
Change
Three Months Ended
March 31,
Prioritized Brands Opdivo $ 1,127 $ 704 60 % $ 761 $ 594 28
% Eliquis 1,101 734 50 % 699 468 49 % Orencia 535 475 13 % 362 321
13 % Sprycel 463 407 14 % 247 210 18 % Yervoy 330 263 25 % 243 199
22 % Empliciti 53 28 89 % 36 28 29 %
Established Brands
Hepatitis C Franchise 162 427 (62 )% 42 259 (84 )% Baraclude 282
291 (3 )% 14 17 (18 )% Sustiva Franchise 184 273 (33 )% 153 228 (33
)% Reyataz Franchise 193 221 (13 )% 88 120 (27 )% Other Brands 499
568 (12 )% 93 93 —
Total $ 4,929 $ 4,391 12 % $ 2,738
$ 2,537 8 %
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
FOR THE THREE MONTHS ENDED MARCH 31, 2017
AND 2016
(Unaudited, dollars and shares in millions
except per share data)
Three Months Ended
March 31,
2017 2016 Net product sales $ 4,580 $ 3,964 Alliance and
other revenues 349 427 Total Revenues 4,929
4,391 Cost of products sold 1,259 1,052 Marketing,
selling and administrative 1,074 1,068 Research and development
1,288 1,136 Other (income)/expense (647 ) (520 ) Total Expenses
2,974 2,736 Earnings Before Income Taxes 1,955
1,655 Provision for Income Taxes 429 449 Net
Earnings 1,526 1,206 Net Earnings/(Loss) Attributable to
Noncontrolling Interest (48 ) 11 Net Earnings Attributable
to BMS $ 1,574 $ 1,195 Average Common Shares
Outstanding: Basic 1,662 1,669 Diluted 1,671 1,680 Earnings
per Common Share Basic $ 0.95 $ 0.72 Diluted $ 0.94 $ 0.71
Other (Income)/Expense Interest expense $ 45 $ 43 Investment income
(33 ) (24 ) Provision for restructuring 164 4 Litigation and other
settlements (484 ) 43 Equity in net income of affiliates (18 ) (26
) Divestiture gains (127 ) (270 ) Royalties and licensing income
(199 ) (254 ) Transition and other service fees (7 ) (53 ) Pension
charges 33 22 Intangible asset impairments — 15 Other (21 ) (20 )
Other (income)/expense $ (647 ) $ (520 )
BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
FOR THE THREE MONTHS ENDED MARCH 31,
2017 AND 2016
(Unaudited, dollars in millions)
Three Months EndedMarch 31, 2017 2016
Cost of
products sold(a) $ — $ 4 License and asset
acquisition charges 50 125 IPRD impairments 75 — Accelerated
depreciation and other 72 13
Research and
development 197 138 Provision for restructuring 164 4
Divestiture gains (100 ) (269 ) Pension charges 33 22 Litigation
and other settlements (481 ) 43 Intangible asset impairments —
15
Other (income)/expense (384 ) (185 )
Decrease to pretax income (187 ) (43 ) Income taxes
on specified items 72 83
Increase/(decrease) to net earnings (115 ) 40
Noncontrolling interest (59 ) —
Increase/(decrease) to net earnings used for diluted Non-GAAP
EPS calculation $ (174 ) $ 40 (a)
Specified items in cost of products sold are accelerated
depreciation, asset impairment and other shutdown costs.
BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN GAAP LINE ITEMS
TO CERTAIN NON-GAAP LINE ITEMS
FOR THE THREE MONTHS ENDED MARCH 31,
2017 AND 2016
(Unaudited, dollars in millions)
Three Months Ended March 31, 2017 GAAP Specified
Items(a)
Non-
GAAP
Gross Profit $ 3,670 $ — $ 3,670 Research and development 1,288
(197 ) 1,091 Other (income)/expense (647 ) 384 (263 ) Earnings
Before Income Taxes 1,955 (187 ) 1,768 Provision for Income Taxes
429 72 357 Noncontrolling interest (48 ) (59 ) 11 Net
Earnings Attributable to BMS used for Diluted EPS Calculation $
1,574 $ (174 ) $ 1,400 Average Common Shares Outstanding -
Diluted 1,671 1,671 1,671 Diluted Earnings Per Share $ 0.94 $ (0.10
) $ 0.84 Effective Tax Rate 21.9 % (1.7 )% 20.2 %
Three Months Ended March 31, 2016 GAAP SpecifiedItems(a) Non-GAAP
Gross Profit $ 3,339 $ 4 $ 3,343 Research and development 1,136
(138 ) 998 Other (income)/expense (520 ) 185 (335 ) Earnings Before
Income Taxes 1,655 (43 ) 1,612 Provision for Income Taxes 449 83
366 Noncontrolling interest 11 — 11 Net Earnings
Attributable to BMS used for Diluted EPS Calculation $ 1,195 $ 40 $
1,235 Average Common Shares Outstanding - Diluted 1,680
1,680 1,680 Diluted Earnings Per Share $ 0.71 $ 0.03 $ 0.74
Effective Tax Rate
27.1 % (4.4 )% 22.7 % (a) Refer to the Specified
Items schedule for further details. Effective tax rate on the
Specified Items represents the difference between the GAAP and
Non-GAAP effective tax rate.
BRISTOL-MYERS SQUIBB COMPANY
NET CASH/(DEBT) CALCULATION
AS OF MARCH 31, 2017 AND DECEMBER 31,
2016
(Unaudited, dollars in millions)
March 31, 2017 December 31, 2016 Cash and cash equivalents $
3,910 $ 4,237 Marketable securities - current 2,199 2,113
Marketable securities - non-current 2,685 2,719
Cash, cash equivalents and marketable securities 8,794 9,069
Short-term debt obligations (1,197 ) (992 ) Long-term debt (7,237 )
(5,716 )
Net cash position $ 360 $ 2,361
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170427005341/en/
Bristol-Myers Squibb CompanyCommunicationsLisa McCormick Lavery,
609-252-7602lisa.mccormicklavery@bms.comorKen Dominski,
609-252-5251ken.dominski@bms.comorInvestor Relations.John Elicker,
609-252-4611john.elicker@bms.comorTim Power,
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024